A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients
Latest Information Update: 26 Mar 2024
At a glance
- Drugs NVP-2203 (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors NVP Healthcare
Most Recent Events
- 21 Mar 2024 Planned primary completion date changed from 31 Mar 2024 to 31 May 2024.
- 03 Oct 2023 Status changed from not yet recruiting to recruiting.
- 16 May 2023 New trial record